Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trial studying the targeted radium alpha pharmaceutical in prostate cancer patients was halted early based on positive survival results.
You may also be interested in...
Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.
Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.
Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases
Some physicians may be concerned by the incidence of osteonecrosis of the jaw reported in pivotal hormone-resistant prostate cancer trial.